SEC Form 8-K Summary
Registrant: Helix Acquisition Corp. (Nasdaq: HLXA), not MoonLake Immunotherapeutics. The filing reports an event dated April 27, 2021 and was filed May 3, 2021. It concerns an executive transition rather than operating or financial results.
Business Context and Reporting Period
Helix Acquisition Corp. was a Cayman Islands special purpose acquisition company. The filing does not provide a financial reporting period or business operating results.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, valuation, or other financial metrics.
Material Changes
- Jay Scollins resigned as Chief Financial Officer effective April 30, 2021.
- The company stated that Mr. Scollins’s resignation was not related to any disagreement with the company or its auditors regarding operations, policies, or practices.
- Andrew Phillips was appointed Chief Financial Officer effective April 30, 2021.
Management, Outlook, and Risks
Dr. Phillips was a Managing Director at Cormorant Asset Management, LP since 2020 and previously served as President and Chief Executive Officer of C4 Therapeutics, Inc. from 2018 to 2020. The filing provides no guidance, outlook, contingency disclosures, unusual financial items, or specific risk updates.
The filing states that Dr. Phillips has no family relationships with any director or executive officer and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Items
- Verify that this filing relates to Helix Acquisition Corp. and not MoonLake Immunotherapeutics.
- Confirm the effective dates of the CFO resignation and appointment: April 30, 2021.
- Review subsequent filings for the impact of the CFO transition and any related business-combination developments.
- Consult the company’s financial statements and other filings for financial metrics not included in this Form 8-K.